Safety and efficacy of JWATM204, a novel Glypican-3 (GPC3)-targeted CAR T cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalation study
{{output}}
Background: Glypican-3 (GPC3) is an important therapeutic target for chimeric antigen receptor (CAR) T cell therapy in hepatocellular carcinoma (HCC). JWATM204 is a novel GPC3-targeted CAR T cell therapy developed on the Antibody... ...
